

Supplemental Digital Content

Supplemental Tables

Table S1: Donor hemodynamics - intention to treat

Variable		N (%) or mean \pm SD				P
		Levothyroxine	Methylprednisolone	Combination	Control	
N		49	50	51	49	
MAP	t ₀	84.5 \pm 18.3	83.4 \pm 15.8	86.9 \pm 19.1	82.2 \pm 18.4	0.602
[60-100 mmHg]		(75.5)	(86.6)	(76.5)	(79.6)	
	t ₄	82.4 \pm 14.9 ^a	89.9 \pm 17.7	96.4 \pm 20.8 ^{ab}	80.8 \pm 13.9 ^b	0.001
		(79.6)	(75.0)	(66.7)	(87.8)	
	t _{OR}	81.4 \pm 12.5	87.3 \pm 14.1	85.7 \pm 16.5	81.4 \pm 13.2	0.137
		(88.3)	(86.7)	(78.7)	(89.5)	
CVP	t ₀	9.1 \pm 4.0	8.1 \pm 3.4	8.9 \pm 4.1	8.8 \pm 3.6	0.569
[4-8 mmHg]		(59.1)	(56.8)	(43.8)	(40.1)	
	t ₄	9.4 \pm 4.5	8.7 \pm 3.5	9.7 \pm 4.1	8.2 \pm 2.7	0.183
		(37.8)	(43.1)	(40.8)	(55.3)	
	t _{OR}	9.9 \pm 4.2 ^c	8.0 \pm 3.2 ^c	9.1 \pm 3.3	8.3 \pm 2.9	0.041
		(39.5)	(59.1)	(45.7)	(52.1)	
PCWP	t ₀	13.0 \pm 8.1	9.5 \pm 3.6	11.5 \pm 6.4	11.8 \pm 5.4	0.115
[6-15 mmHg]		(73.6)	(83.3)	(66.7)	(78.4)	
	t ₄	12.5 \pm 6.3	10.9 \pm 3.5	12.7 \pm 5.5	11.9 \pm 5.4	0.430
		(71.7)	(87.1)	(74.4)	(80.1)	
	t _{OR}	11.9 \pm 3.2	11.0 \pm 3.9	11.2 \pm 3.9	10.9 \pm 4.3	0.739
		(85.7)	(78.9)	(77.1)	(85.0)	
CI	t ₀	3.2 \pm 1.3	3.1 \pm 1.1	3.3 \pm 1.4	3.0 \pm 0.8	^d
[\geq 2.5 L/min/m ²]		(67.5)	(68.4)	(73.7)	(76.8)	
	t ₄	3.1 \pm 0.9	3.3 \pm 1.2	3.6 \pm 1.4	3.3 \pm 1.2	^d
		(66.7)	(79.5)	(90.7)	(70.5)	
	t _{OR}	3.4 \pm 0.9	3.9 \pm 1.3	3.7 \pm 0.9	3.5 \pm 1.0	^d
		(86.5)	(91.9)	(89.7)	(86.0)	
VIS	t ₀	16.3 \pm 16.1	20.5 \pm 27.8	14.7 \pm 17.4	16.5 \pm 17.4	^e
	t ₄	16.3 \pm 14.5	12.9 \pm 15.4	11.3 \pm 11.8	14.4 \pm 12.3	^e
	t _{OR}	13.0 \pm 14.8	4.9 \pm 5.7	3.7 \pm 5.5	9.2 \pm 8.0	^e

^aP < 0.05

^bP < 0.05

^cP < 0.05

^dSee Figure 3A for statistical comparison using linear mixed model methodology

^eSee Figure 2A for statistical comparison using linear mixed model methodology

Table S2: Donor hemodynamics - per protocol

Variable		N (%) or mean \pm SD				P
		Levothyroxine	Methylprednisolone	Combination	Control	
N		41	37	76	28	
MAP	t ₀	82.9 \pm 17.0	84.1 \pm 15.6	85.0 \pm 18.9	85.8 \pm 18.7	0.921
[60-100 mmHg]		(78.0)	(83.7)	(76.3)	(78.6)	
	t ₄	83.3 \pm 14.5	88.6 \pm 16.8	92.5 \pm 21.5 ^a	81.0 \pm 10.4 ^a	0.011
		(85.0)	(75.7)	(75.0)	(92.9)	
	t _{OR}	81.1 \pm 12.1	88.2 \pm 14.2	83.2 \pm 15.4	84.8 \pm 13.9	0.163
		(87.5)	(86.5)	(82.1)	(85.7)	
CVP	t ₀	8.8 \pm 3.4	7.4 \pm 3.0	9.4 \pm 4.3	8.4 \pm 3.3	0.083
[4-8 mmHg]		(60.5)	(61.8)	(34.3)	(57.7)	
	t ₄	9.1 \pm 4.1	8.0 \pm 3.3	9.4 \pm 4.0	8.6 \pm 2.8	0.302
		(35.9)	(47.1)	(44.6)	(51.9)	
	t _{OR}	9.8 \pm 4.2 ^b	7.6 \pm 2.8 ^b	9.0 \pm 3.3	8.3 \pm 3.1	0.038
		(40.0)	(66.7)	(44.6)	(51.9)	
PCWP	t ₀	13.1 \pm 8.8	9.0 \pm 3.1	12.0 \pm 5.8	11.1 \pm 4.6	0.057
[6-15 mmHg]		(71.9)	(89.7)	(66.1)	(84.2)	
	t ₄	12.3 \pm 6.3	10.4 \pm 3.4	12.3 \pm 4.9	12.3 \pm 5.1	0.331
		(69.7)	(90.6)	(78.3)	(82.6)	
	t _{OR}	11.8 \pm 3.1	10.3 \pm 3.6	11.4 \pm 3.8	11.7 \pm 5.3	0.397
		(87.9)	(84.4)	(78.6)	(76.2)	
CI	t ₀	3.4 \pm 1.4	3.1 \pm 1.0	3.1 \pm 1.0	2.9 \pm 0.7	^c
[\geq 2.5 L/min/m ²]		(67.6)	(70.0)	(74.6)	(76.2)	
	t ₄	3.1 \pm 0.9	3.4 \pm 1.2	3.3 \pm 1.1	3.2 \pm 0.9	^c
		(64.7)	(81.3)	(79.4)	(76.0)	
	t _{OR}	3.4 \pm 0.8	4.0 \pm 1.3	3.7 \pm 1.1	3.3 \pm 0.9	^c
		(88.2)	(93.3)	(89.6)	(79.2)	
VIS	t ₀	15.8 \pm 16.0	12.1 \pm 13.3	19.3 \pm 20.7	10.3 \pm 8.8	^d
	t ₄	16.2 \pm 13.7	9.5 \pm 10.3	16.0 \pm 15.4	9.0 \pm 7.6	^d
	t _{OR}	11.1 \pm 11.7	4.1 \pm 5.2	7.3 \pm 10.7	8.5 \pm 7.3	^d

^aP < 0.05^cSee Figure 3B for statistical comparison using linear mixed model methodology^bP < 0.05^dSee Figure 2B for statistical comparison using linear mixed model methodology

Note: If homogeneity of variance was violated, reported P-values are Brown-Forsythe robust test of equality of means with Games-Howell post-hoc corrections

Table S3: Organ specific outcomes - per protocol**Heart**

Variable	N (%) or mean \pm SD					P
	All	Levothyroxine	Methylprednisolone	Combination	Control	
N	65	11	14	33	7	
Age	52.8 \pm 13.2	58.3 \pm 7.9	50.3 \pm 14.1	51.6 \pm 14.7	55.4 \pm 7.6	0.428
Female	21 (32%)	3 (27%)	5 (36%)	10 (30%)	3 (43%)	0.892
Race						0.99
White/Caucasian	34 (56%)	6 (55%)	7 (54%)	17 (55%)	4 (67%)	
Black/AA	23 (38%)	4 (36%)	5 (38%)	12 (39%)	2 (33%)	
Hispanic/Latino	3 (5%)	1 (9%)	1 (8%)	1 (3%)	0 (0%)	
Other	1 (2%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)	
Blood Type						0.083
A/A1	23 (38%)	3 (30%)	5 (42%)	11 (34%)	4 (67%)	
O	23 (38%)	5 (50%)	1 (8%)	15 (47%)	2 (33%)	
B	12 (20%)	1 (10%)	5 (42%)	6 (19%)	0 (0%)	
AB	2 (3%)	1 (10%)	1 (8%)	0 (0%)	0 (0%)	
BMI	27 \pm 5.2	28.3 \pm 4.3	27.8 \pm 5.1	26.1 \pm 5.7	27.7 \pm 4.1	0.587
UNOS Status						0.284
1A	30 (53%)	3 (27%)	7 (64%)	18 (62%)	2 (33%)	
1B	23 (40%)	7 (64%)	4 (36%)	9 (31%)	3 (50%)	
2	4 (7%)	1 (9%)	0 (0%)	2 (7%)	1 (17%)	
Cold Ischemic Time (min)	194 \pm 68	193 \pm 53	220 \pm 51	189 \pm 83	170 \pm 46	0.48
Warm Ischemic Time (min)	61.7 \pm 26.7	54.6 \pm 31.6	69.8 \pm 31.8	63.3 \pm 26.2	58.0 \pm 8.3	0.759
Bypass Time (min)	93.7 \pm 64	107.3 \pm 61.2	99.2 \pm 77.9	95.4 \pm 65.2	56.2 \pm 35.6	0.47
VIS-ICU arrival	16.8 \pm 15.6	9.4 \pm 5.0	17.1 \pm 10.8	18.9 \pm 19.3	14.6 \pm 7.3	0.601
Cardiac Index-ICU arrival	2.8 \pm 1	2.6 \pm 0.6	2.6 \pm 1.2	2.7 \pm 0.9	3.6 \pm 1.2	0.182
VIS-24 hr	12.8 \pm 11.4	12.1 \pm 8.8	12.8 \pm 17.2	14.0 \pm 10.5	6.2 \pm 3.6	0.667
Cardiac Index-24 hr	2.9 \pm 0.7	2.8 \pm 0.6	2.6 \pm 0.3	2.9 \pm 0.9	3.3 \pm 0.4	0.329
VIS-48 hr	10.9 \pm 12	6.7 \pm 5.8	9.4 \pm 16.7	13.4 \pm 11.3	7.4 \pm 9.0	0.622
Cardiac Index-48 hr	3.1 \pm 0.9	2.5 \pm 0.5 ^a	3.8 \pm 1.4 ^a	3.0 \pm 0.6	2.9 \pm 0.4	0.042
Cardiac Index-30 days	3.3 \pm 0.7	3.3 \pm 0.8	3.0 \pm 0.8	3.4 \pm 0.6	3.4 \pm 0.5	0.625
PCWP-30 days	13.4 \pm 6	13.9 \pm 5.2	9.5 \pm 5.6	13.9 \pm 6.4	15.7 \pm 3.8	0.214
Ejection Fraction-30 days	0.59 \pm 0.11	0.66 \pm 0.08	0.60 \pm 0.06	0.57 \pm 0.13	0.59 \pm 0.04	0.239
Mechanical Support	13 (23%)	3 (27%)	2 (18%)	8 (28%)	0 (0%)	0.629
Type of Mechanical Support						0.538
IABP	7 (54%)	1 (33%)	1 (50%)	5 (63%)	0 (0%)	
RVAD	3 (23%)	1 (33%)	0 (0%)	2 (25%)	0 (0%)	
ECMO	2 (15%)	0 (0%)	1 (50%)	1 (13%)	0 (0%)	

<i>Variable</i>	N (%) or mean \pm SD					<i>P</i>
	<i>All</i>	<i>Levothyroxine</i>	<i>Methylprednisolone</i>	<i>Combination</i>	<i>Control</i>	
BIVAD	1 (8%)	1 (33%)	0 (0%)	0 (0%)	0 (0%)	
Days in Hospital	26.9 \pm 28.8	16.6 \pm 7.1 ^b	13.7 \pm 5.2 ^c	37.2 \pm 36.2 ^{bcd}	14.5 \pm 6.7 ^d	0.037
Mortality by 90 days	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1.0

^a*P* < 0.05

^b*P* < 0.05

^c*P* < 0.05

^d*P* < 0.05

Lung

Variable	N (%) or mean \pm SD					P
	All	Levothyroxine	Methylprednisolone	Combination	Control	
N	63	11	11	31	10	
Age	56.9 \pm 12.6	58.1 \pm 12.5	59.6 \pm 6.7	56.8 \pm 12.0	53.0 \pm 19.0	0.69
Female	22 (35%)	3 (27%)	6 (55%)	12 (39%)	1 (10%)	0.174
Race						0.104
White/Caucasian	47 (81%)	9 (90%)	11 (100%)	23 (82%)	4 (44%)	
Black/AA	5 (9%)	0 (0%)	0 (0%)	3 (11%)	2 (22%)	
Hispanic/Latino	3 (5%)	0 (0%)	0 (0%)	1 (4%)	2 (22%)	
Other	3 (5%)	1 (10%)	0 (0%)	1 (4%)	1 (11%)	
Blood Type						0.301
O	32 (52%)	5 (45%)	4 (36%)	15 (52%)	8 (80%)	
A/A1	21 (34%)	6 (55%)	4 (36%)	10 (34%)	1 (10%)	
B	5 (8%)	0 (0%)	2 (18%)	3 (10%)	0 (0%)	
AB	3 (5%)	0 (0%)	1 (9%)	1 (3%)	1 (10%)	
BMI	25.8 \pm 4.6	26.5 \pm 2.6	28.2 \pm 5.6	24.8 \pm 4.8	24.4 \pm 3.6	0.154
Double Lung Transplant	45 (71%)	8 (73%)	7 (64%)	22 (71%)	8 (80%)	0.914
Cold Ischemic Time (min)	298 \pm 70	256 \pm 47	302 \pm 78	297 \pm 73	334 \pm 60	0.168
Warm Ischemic Time (min)	61.1 \pm 22.5	74.3 \pm 40.8	75.6 \pm 23.0	54.3 \pm 17.6	52.2 \pm 10.6	0.185
FiO ₂ -ICU arrival	0.52 \pm 0.26	0.54 \pm 0.25	0.59 \pm 0.31	0.50 \pm 0.27	0.45 \pm 0.23	0.685
FiO ₂ -discharge	0.24 \pm 0.12	0.21 \pm 0.00	0.25 \pm 0.04	0.27 \pm 0.18	0.22 \pm 0.03	0.596
SaO ₂ -ICU arrival	0.96 \pm 0.07	0.97 \pm 0.03	0.97 \pm 0.04	0.96 \pm 0.07	0.92 \pm 0.13	0.466
SaO ₂ -discharge	0.96 \pm 0.03	0.96 \pm 0.02	0.97 \pm 0.03	0.96 \pm 0.03	0.97 \pm 0.04	0.91
Days Intubated	6.6 \pm 16.9	3.1 \pm 3.2	6.4 \pm 11.4	4.9 \pm 7.6	15.9 \pm 38.1	0.387
Reintubation	15 (29%)	1 (10%)	5 (45%)	6 (29%)	3 (30%)	0.369
Nitric Oxide	17 (33%)	2 (20%)	2 (18%)	9 (45%)	4 (40%)	0.409
Anastomotic Complication	3 (6%)	0 (0%)	1 (9%)	2 (10%)	0 (0%)	0.79
Days in Hospital	31 \pm 21.5	24.7 \pm 16.5	38.0 \pm 28.1	25.9 \pm 11.9	40.7 \pm 30.4	0.152
Mortality by 30 Days	1 (2%)	0 (0%)	1 (9%)	0 (0%)	0 (0%)	0.586
Mortality by 90 Days	3 (6%)	0 (0%)	2 (18%)	1 (5%)	0 (0%)	0.343

Liver

Variable	N (%) or mean \pm SD					P
	All	Levothyroxine	Methylprednisolone	Combination	Control	
N	145	34	28	57	26	
Age	55.3 \pm 9.3	56.0 \pm 9.0	57.0 \pm 7.8	53.9 \pm 10.7	55.6 \pm 7.6	0.512
Female	46 (32%)	15 (44%)	7 (25%)	19 (34%)	5 (19%)	0.174
Race						0.637
White/Caucasian	116 (82%)	27 (79%)	22 (79%)	47 (87%)	20 (77%)	
Black/AA	19 (13%)	5 (15%)	5 (18%)	6 (11%)	3 (12%)	
Hispanic/Latino	4 (3%)	1 (3%)	0 (0%)	1 (2%)	2 (8%)	
Other	3 (2%)	1 (3%)	1 (4%)	0 (0%)	1 (4%)	
Blood Type						0.617
O	64 (44%)	14 (41%)	9 (33%)	30 (53%)	11 (42%)	
A/A1	49 (34%)	13 (38%)	8 (30%)	17 (30%)	11 (42%)	
B	21 (15%)	5 (15%)	7 (26%)	7 (12%)	2 (8%)	
AB	10 (7%)	2 (6%)	3 (11%)	3 (5%)	2 (8%)	
BMI	28.4 \pm 5	28.1 \pm 4.9	29.4 \pm 5.0	28.3 \pm 5.1	27.9 \pm 5.2	0.718
MELD score	21.4 \pm 5.1	22.1 \pm 5.3	21.3 \pm 5.6	21.7 \pm 4.8	19.9 \pm 4.8	0.391
Cold Ischemic Time (min)	376 \pm 104	386 \pm 128	396 \pm 118	362 \pm 86	377 \pm 94	0.525
Warm Ischemic Time (min)	40 \pm 14.3	44.8 \pm 21.7	40.9 \pm 10.7	39.6 \pm 11.5	34.2 \pm 10.4	0.061
Total Bilirubin-peak (mg/dL)	6.1 \pm 4.5	5.4 \pm 3.0	5.1 \pm 2.8	6.7 \pm 4.8	6.8 \pm 6.1	0.294
Direct Bilirubin-peak (mg/dL)	3.1 \pm 2.5	2.6 \pm 1.9	2.2 \pm 1.2	3.4 \pm 3.1	3.6 \pm 2.5	0.249
AST-peak (U/L)	1548 \pm 1642	1732 \pm 2068	1258 \pm 1255	1323 \pm 1385	2128 \pm 1876	0.138
AST-discharge (U/L)	119 \pm 491.6	79.0 \pm 78.1	293 \pm 1123	74.5 \pm 69.9	87.9 \pm 79.8	0.263
ALT-peak (U/L)	782 \pm 715	787 \pm 777	704 \pm 580	768 \pm 797	885 \pm 585	0.836
ALT-discharge (U/L)	213 \pm 269	205 \pm 198	286 \pm 506	181 \pm 159	221 \pm 173	0.434
Lactate-peak (mmol/L)	2.6 \pm 2.4	2.7 \pm 2.9	3.2 \pm 2.7	2.4 \pm 2.3	2.1 \pm 1.6	0.602
INR-24 hr	1.34 \pm 0.32	1.40 \pm 0.48	1.36 \pm 0.24	1.32 \pm 0.30	1.31 \pm 0.20	0.767
INR-48 hr	1.61 \pm 0.49	1.71 \pm 0.80	1.58 \pm 0.40	1.56 \pm 0.34	1.65 \pm 0.38	0.535
Factor V-24 hr (% activity)	0.75 \pm 0.33	0.82 \pm 0.43	0.78 \pm 0.29	0.75 \pm 0.31	0.68 \pm 0.30	0.639
Factor V-48 hr (% activity)	0.98 \pm 0.28	1.11 \pm 0.43	0.89 \pm 0.24	0.98 \pm 0.24	0.92 \pm 0.20	0.423
Primary Graft Non-function	1 (1%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0.36
Plasmapheresis	1 (1%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)	1.0
Bile Duct Complication	9 (7%)	0 (0%)	2 (8%)	5 (9%)	2 (8%)	0.371
Thrombosis	6 (4%)	3 (10%)	0 (0%)	3 (5%)	0 (0%)	0.288
Days in Hospital	9.3 \pm 8.8	9.2 \pm 7.7	7.2 \pm 3.9	9.9 \pm 9.5	10.1 \pm 11.7	0.572
Allograft Failure	5 (4%)	1 (3%)	2 (8%)	2 (4%)	0 (0%)	0.577
Mortality by 30 Days	3 (2%)	2 (7%)	1 (4%)	0 (0%)	0 (0%)	0.126
Mortality by 90 Days	5 (4%)	2 (7%)	1 (5%)	2 (4%)	0 (0%)	0.709

Kidney

Variable	N (%) or mean \pm SD					P
	All	Levothyroxine	Methylprednisolone	Combination	Control	
N	277	56	55	124	42	
Age	51.6 \pm 13.8	50.3 \pm 13.4	52.3 \pm 13.4	51.4 \pm 14.5	53.1 \pm 12.7	0.753
Female	120 (43%)	21 (38%)	31 (56%)	55 (44%)	13 (31%)	0.064
Race						0.534
Black/AA	155 (58%)	31 (55%)	34 (63%)	67 (57%)	23 (55%)	
White/Caucasian	102 (38%)	24 (43%)	20 (37%)	43 (37%)	15 (36%)	
Hispanic/Latino	7 (3%)	1 (2%)	0 (0%)	3 (3%)	3 (7%)	
Other	5 (2%)	0 (0%)	0 (0%)	4 (3%)	1 (2%)	
Blood Type						0.445
O	114 (42%)	19 (34%)	19 (35%)	58 (49%)	18 (44%)	
A/A1	93 (35%)	22 (39%)	19 (35%)	37 (31%)	15 (37%)	
B	47 (17%)	12 (21%)	13 (24%)	18 (15%)	4 (10%)	
AB	15 (6%)	3 (5%)	3 (6%)	5 (4%)	4 (10%)	
BMI	28.7 \pm 5.9	29.0 \pm 5.8	28.9 \pm 6.8	28.4 \pm 5.8	29.1 \pm 5.1	0.901
Cold Ischemic Time (min)	992 \pm 466	1027 \pm 527	1021 \pm 532	977 \pm 444	952 \pm 354	0.827
Warm Ischemic Time (min)	35.7 \pm 9.3	35.8 \pm 11.2	35.0 \pm 7.6	36.2 \pm 9.7	35.1 \pm 7.7	0.835
Pump Time (min)	541 \pm 296	607 \pm 310	531 \pm 259	534 \pm 306	498 \pm 299	0.571
Urine Output first 24 hrs (mL)	3909 \pm 3494	4228 \pm 3907	3877 \pm 4188	3823 \pm 3220	3823 \pm 2795	0.922
Creatinine-highest (mg/dL)	7.5 \pm 3.5	7.0 \pm 3.2 ^e	6.7 \pm 3.0 ^f	7.6 \pm 3.5	9.0 \pm 3.8 ^{ef}	0.009
Creatinine-at discharge (mg/dL)	4.2 \pm 3.1	3.5 \pm 2.7 ^g	3.6 \pm 2.5 ^h	4.4 \pm 3.2	5.3 \pm 3.7 ^{gh}	0.016
Creatinine-30 days (mg/dL)	1.9 \pm 1.39	1.70 \pm 1.18	1.67 \pm 1.19	1.97 \pm 1.51	2.3 \pm 1.5	0.128
Creatinine-90 days (mg/dL)	1.68 \pm 0.97	1.47 \pm 0.47 ⁱ	1.59 \pm 0.88	1.71 \pm 1.05	2.0 \pm 1.2 ⁱ	0.048
Post-transplant Dialysis	57 (22%)	14 (27%)	9 (17%)	25 (21%)	9 (23%)	0.697
Chronic Dialysis	9 (3%)	1 (2%)	1 (2%)	5 (4%)	2 (5%)	0.805
Ureteral Complication	11 (4%)	2 (4%)	0 (0%)	7 (6%)	2 (5%)	0.347
Thrombosis	1 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1.0
Days in Hospital	4.9 \pm 3.5	6.2 \pm 5.5	4.6 \pm 1.8	4.7 \pm 2.9	4.2 \pm 3.2	0.022
Allograft Failure	6 (2%)	0 (0%)	0 (0%)	4 (3%)	2 (5%)	0.201
Mortality by 90 Days	3 (1%)	0 (0%)	1 (2%)	2 (2%)	0 (0%)	1.0

^eP < 0.05

^fP < 0.05

^gP < 0.05

^hP < 0.05

ⁱP < 0.05

Pancreas

Variable	N (%) or mean \pm SD					P
	All	Levothyroxine	Methylprednisolone	Combination	Control	
N	21	5	5	10	1	
Age	42.9 \pm 9.1	46.6 \pm 7.7	43.0 \pm 14.2	41.3 \pm 7.1	38	0.74
Female	7 (33%)	2 (40%)	2 (40%)	3 (30%)	0 (0%)	1.0
Black/AA	11 (55%)	3 (60%)	3 (60%)	5 (56%)	0 (0%)	1.0
Blood Type						0.4
O	11 (52%)	2 (40%)	2 (40%)	6 (60%)	1 (100%)	
A/A1	6 (29%)	1 (20%)	1 (20%)	4 (40%)	0 (0%)	
B	3 (14%)	2 (40%)	1 (20%)	0 (0%)	0 (0%)	
AB	1 (5%)	0 (0%)	1 (20%)	0 (0%)	0 (0%)	
BMI	24 \pm 3.6	24.6 \pm 4.0	23.3 \pm 2.0	24.7 \pm 4.0	18.2	0.381
Cold Ischemic Time (min)	669 \pm 166	698 \pm 288	682 \pm 121	645 \pm 123	665	0.956
Warm Ischemic Time (min)	33.1 \pm 14.6	39.6 \pm 27.8	25.4 \pm 5.1	33.1 \pm 6.6	38	0.512
HbA1C-14 days (%)						
C-Peptide-14 days (ng/mL)	4.9 \pm 6.6	-	-	4.9 \pm 6.6	-	
Insulin Requirement	4 (21%)	0 (0%)	1 (20%)	3 (33%)	0 (0%)	0.812
Thrombosis	3 (15%)	0 (0%)	0 (0%)	3 (33%)	0 (0%)	0.333
Days in Hospital	6.1 \pm 1.8	5.6 \pm 0.5	7.4 \pm 1.9	5.7 \pm 1.9	5	0.268
Allograft Failure	4 (20%)	0 (0%)	0 (0%)	4 (44%)	0 (0%)	0.187
Mortality by 90 days	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1.0

Note: If homogeneity of variance was violated, reported *P*-values are Brown-Forsythe robust test of equality of means with Games-Howell post-hoc corrections